As the American Society of Clinical Oncology (ASCO) annual meeting ended in Chicago, many outstanding clinical advances came during the conference. Undoubtedly, those companies that have been optimistic about the industry have received much attention during the conference. Of course, during the ASCO meeting every year, there will always be a "dark horse" to bring surprises to the industry.
Big winner: the entire CAR-T queue
As a revolutionary new cancer therapy, CAR-T cell therapy is a hot topic before the ASCO annual meeting. The industry has resisted it hysterically and is looking forward to it. At this year's ASCO, well-known CAR-T therapy companies such as bluebird bio/Celgene, Kite, and Juno announced the latest data on CAR-T therapy, which once again aroused positive emotions in the industry.
Nanjing Legend Biotechnology Co., Ltd.: Dark horse from China
This year's ASCO annual meeting of the black horse is Nanjing Legend Biotechnology Co., Ltd., a low-key Chinese company established in 2014, focusing on the research and development of chimeric antigen receptor cell technology in immunotherapy. Its CAR-T therapy has shown excellent results in the treatment of multiple myeloma.
LCAR-B38M is a CAR-T therapy for BCMA developed by Nanjing Legend. According to the data, the objective response rate of this therapy reached 100% in a clinical trial involving 35 patients with relapsed or drug-resistant multiple myeloma. Among the 19 patients who were the first to receive treatment, Nanjing Legend followed up for 4-14 months. Among them, 14 patients continued to meet the strict diagnostic criteria for complete response, and 5 patients had partial remission.
(Source: Nanjing Legend Biotechnology Co., Ltd.)
According to Dr. Frank Fan, the chief scientist of Nanjing Legend, the company plans to recruit 100 patients in clinical trials in China and conduct trials in the United States in early 2018. The company's largest investor is Nanjing Kingsray Biotech Co., Ltd., a multinational company that provides contract research and development services for pharmaceutical companies and other companies.
Bluebird Bio: Record of no recurrence
Bluebird bio hopes that CAR-T is more than just a special treatment for cells. The company, which landed on NASDAQ in 2013, is based on its unique lentiviral vector platform technology and is dedicated to gene editing based gene therapy for severe hereditary diseases and cancer.
In 2015, Bluebird Bio acquired the exclusive rights of human antibodies provided by Five Prime, and cooperated in the development and commercialization of CAR-T cell therapy, officially indicating that Bluebird Bio entered the competition team of CAR-T project.
At this year's ASCO annual meeting, the CAR-T therapy bb2121, jointly developed by Bluebird Bio and Celgene, demonstrated excellent results in the treatment of multiple myeloma. Of the 31 clinical trials recruited, after receiving bb2121 treatment, data from 15 patients were used for efficacy evaluation. Of these, 27% had complete remission and 47% had good partial remission. The median number of treatments these patients had received was as high as seven, meaning that the treatment options they could use were extremely limited.
(Source: Bluebird Bio official website)
living room lounge chairs,Living Room Chairs,living room half recliner chairs
Guangzhou LoPhiDa Co.Ltd , https://www.guangdongwidinlsa.com